Bicara Therapeutics (BCAX) Share-based Compensation (2024 - 2026)

Bicara Therapeutics' Share-based Compensation history runs 3 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 69.75% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 55.83% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 74.61% from the prior year.
• Share-based Compensation rose to $5.9 million in Q1 2026 per BCAX's latest filing, from -$8.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.4 million in Q4 2024 and bottomed at -$8.7 million in Q4 2025.
• The 3-year median for Share-based Compensation is $3.5 million (2025), against an average of $1.9 million.
• Biggest YoY gain for Share-based Compensation was 404.45% in 2025; the steepest drop was 217.33% in 2025.
• Year by year, Share-based Compensation stood at $7.4 million in 2024, then tumbled by 217.33% to -$8.7 million in 2025, then jumped by 167.5% to $5.9 million in 2026.
• Per Business Quant, the three latest BCAX Share-based Compensation figures stand at $5.9 million (Q1 2026), -$8.7 million (Q4 2025), and $3.6 million (Q3 2025).